Breast Cancer

CON: Katherine Mandock, PharmD, BCPS; Scott A. Soefje, PharmD, BCOP
PRO: Val R. Adams, PharmD, BCOP, FCCP

The Case Against Appoval

Dual HER2 blockade with trastuzumab plus pertuzumab combined with docetaxel chemotherapy significantly extended progression- free survival (PFS) by about 6 months compared to trastuzumab plus docetaxel plus placebo in patients with metastatic HER2+ breast cancer, according to results from the CLEOPATRA trial presented at the CTRC-AACR San Antonio Breast Cancer Symposium.

Promising data on several new breast cancer agents, including one new cytotoxic, were presented at the American Society of Clinical Oncology Breast Cancer Symposium 2011 held September 8-10 in San Francisco, California.

The addition of the novel histone deacetylase (HDAC) inhibitor entinostat to exemestane significantly delayed recurrences and showed a trend for a survival benefit in the phase 2 ENCORE 301 (ENtinostat Combinations Overcoming REsistance) study reported by Denise Yardley, MD, of Sarah Cannon Research Institute and Tennessee Oncology in Nashville.

Bevacizumab (Avastin; Genentech) for metastatic breast cancer may be one of the most widely debated, media-reported, and editorialized agents in oncology.

CHICAGO—In the National Cancer Institute of Canada Clinical Trials Group MA.20 trial, regional nodal irradiation (RNI) added to whole breast irradiation (WBI) improved disease- free survival (DFS), with a trend toward improved overall survival (OS), reported Timothy Whelan, MD, of McMaster University and the Juravinski Cancer Centre in Hamilton, Ontario.

SAN ANTONIO—A rapidly growing, nationwide clinical trial matching service that is user-friendly for patients is enabling more patients to learn about and enroll in clinical trials, said Ellie Cohen, PhD, the program’s director. Cohen described the success of her program at the 33rd annual San Antonio Breast Cancer Symposium.

Bevacizumab (Avastin; Genentech) for metastatic breast cancer may be one of the most widely debated, media-reported, and editorialized agents in oncology.

For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.

For breast cancer patients aged 66 years and older, nurses should consider comorbidities when discussing prognosis, according to an analysis of Surveillance, Epidemiology and End Results–Medicare data.

CHICAGO—Exemestane appears to be a good alternative to tamoxifen for prevention of breast cancer in postmenopausal women, according to results of the randomized, placebo-controlled MAP.3 trial.
Page 12 of 17
Results 111 - 120 of 161